ACLX250516C55000
- 3.60
- +2.40+200.00%
Arcellx Newsroom
A Quick Look at Today's Ratings for Arcellx(ACLX.US), With a Forecast Between $93 to $115
Arcellx Analyst Ratings
Arcellx Inc (ACLX) Receives a Buy From Scotiabank
Analysts' Opinions Are Mixed on These Healthcare Stocks: Arcellx Inc (ACLX), Vir Biotechnology (VIR) and Liquidia Technologies (LQDA)
Promising Potential of Arcellx Inc's Anito-cel Program Drives Buy Rating
CCORF Maintains Arcellx(ACLX.US) With Buy Rating, Maintains Target Price $121
William Blair Maintains Arcellx(ACLX.US) With Buy Rating
William Blair Sticks to Its Buy Rating for Arcellx Inc (ACLX)
Analysts Are Bullish on These Healthcare Stocks: Illumina (ILMN), Arcellx Inc (ACLX)
Barclays Maintains Arcellx(ACLX.US) With Buy Rating, Maintains Target Price $115
Stifel Maintains Arcellx(ACLX.US) With Buy Rating, Cuts Target Price to $118
A Quick Look at Today's Ratings for Arcellx(ACLX.US), With a Forecast Between $105 to $134
Bank of America Securities Keeps Their Buy Rating on Arcellx Inc (ACLX)
A Quick Look at Today's Ratings for Arcellx(ACLX.US), With a Forecast Between $105 to $134
Arcellx Inc: Buy Rating Affirmed on Promising Anito-cel Therapy and Strong Financial Position
Analysts Have Conflicting Sentiments on These Healthcare Companies: Arcellx Inc (ACLX) and PTC Therapeutics (PTCT)
Stifel Maintains Arcellx(ACLX.US) With Buy Rating, Maintains Target Price $122
Stifel Maintains Arcellx(ACLX.US) With Buy Rating, Maintains Target Price $122
CCORF Maintains Arcellx(ACLX.US) With Buy Rating, Maintains Target Price $121
Buy Rating for Arcellx Inc. Based on Promising Efficacy and Safety of BCMA CAR-T Therapy in IMMagine-1 Study